Female Infertility Diagnosis and Treatment Market
Female Infertility Diagnosis and Treatment Market Research and Analysis, 2017-2022
The global female infertility diagnosis and treatment market was estimated to USD 21,820 million in 2018 and expected to grow with the CAGR of 4.7% during the forecast period. The major factors that are augmenting the growth of the female infertility market are changing life style and increasing IVF market. Furthermore, rising trend of surrogacy, growing infertility rate among female, new technologies to avoid multiple embryo implants are the also estimated to be the major factors that are contributing significantly towards the growth of the market.
Updated version (2019-2025) of the report
is available @ https://www.omrglobal.com/industry-reports/female-infertility-market-size
However, there are certain factors that are affecting the growth of the market. High cost infertility treatment, low accuracy rate of the treatment and social stigma related to the infertility treatment are the major factors constraints that are hindering the growth of the global Female Infertility Diagnosis and Treatment Market across the globe.
Global female infertility market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of the geography, market is bifurcated into North America, Europe, Asia Pacific and Rest of the World. North America is estimated to be the leading region in the global infertility market. Increasing IVF market is also one of the major factor driving the growth of the market in the region. Asia Pacific is estimated to be the fastest growing region during the forecast period 2017-2022.
Key players of the female infertility market are Bayer Ag, Bristol-Myers Squibb Co, Church & Dwight Company Inc., Cook Medical Inc., Coopersurgical Inc, Eli Lilly & Co., Emd Serono Inc, Endo Pharmaceuticals Inc, Ferring Pharmaceuticals, Genea, GlaxoSmithKline Plc, Halotech DNA, Irvine Scientific, Janssen Pharmaceutical, Merck Serono, Novartis International Ag, Origio, Ovascience, Pfizer Inc, and Princeton. In order to survive in the market these players adopt different marketing strategies such as merger, acquisitions, product launch, and geographical expansion so on. For Example: In 2016, Bayer AG acquired Monsanto a US based company in a $66 billion deal.
The Report covers
• Comprehensive research methodology of global female infertility market
• This report also includes detailed and extensive market overview with Analyst insights & key market trends.
• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global female infertility market
• Insights about market determinants which are stimulating the global female infertility market
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. CHANGING LIFE STYLE
3.1.2. RISING TREND OF SURROGACY
3.1.3. INCREASING FEMALE GERIATRIC POPULATION
3.1.4. NEW TECHNOLOGIES TO AVOID MULTIPLE EMBRYO IMPLANTS
3.1.5. INCREASING IVF TREAMENT MARKET
3.1.6. GROWING INFERTILITY RATE AMONG FEMALE
3.2. RESTRAINTS
3.2.1. HIGH COST OF TREATMENT
3.2.2. INCREASING INCIDENCES OF TREATMENT FAILURES
3.2.3. SOCIAL STIGMA RELATED TO INFERTILITY TREATMENT
3.3. OPPORTUNITIES
3.3.1. INCREASING MEDICAL TOURISM
3.3.2. INCREASING AWARENESS AMONG PEOPLE
4. MARKET SEGMENTATION
4.1. GLOBAL FEMALE INFERTILITY MARKET BY DIAGNOSIS
4.1.1. OVULATION TESTING MARKET
4.1.2. HYSTEROSALPINGOGRAPHY MARKET
4.1.3. HYSTEROSCOPY MARKET
4.1.4. IMAGING TESTING MARKET
4.1.5. OVARIAN RESERVE TESTING MARKET
4.1.6. HORMONAL LEVEL TESTING MARKET
4.1.7. GENETIC TESTING MARKET
4.1.8. OTHERS
4.2. GLOBAL FEMALE INFERTILITY MARKET BY TREATMENT
4.2.1. DRUGS AND MEDICINE MARKET
4.2.2. SURGICAL MARKET
4.2.3. INTRAUTERINE INSEMINATION (IUI) MARKET
4.2.4. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET
4.2.5. OTHERS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. BAYER AG
7.1.1. INTRODUCTION
7.1.2. BAYER AG PRODUCT PORTFOLIO
7.1.3. BAYER AG RECENT ACTIVITIES
7.2. BRISTOL-MYERS SQUIBB CO.
7.2.1. INTRODUCTION
7.2.2. BRISTOL-MYERS SQUIBB CO. PRODUCT PORTFOLIO
7.2.3. BRISTOL-MYERS SQUIBB CO. RECENT ACTIVITIES
7.3. CHURCH & DWIGHT COMPANY INC.
7.3.1. INTRODUCTION
7.3.2. CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO
7.3.3. CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES
7.4. COOK MEDICAL, INC.
7.4.1. INTRODUCTION
7.4.2. COOK MEDICAL, INC. PRODUCT PORTFOLIO
7.4.3. COOK MEDICAL, INC. RECENT ACTIVITIES
7.5. COOPERSURGICAL INC.
7.5.1. INTRODUCTION
7.5.2. COOPERSURGICAL INC. PRODUCT PORTFOLIO
7.5.3. COOPERSURGICAL INC. RECENT ACTIVITIES
7.6. ELI LILLY & CO.
7.6.1. INTRODUCTION
7.6.2. ELI LILLY & CO. PRODUCT PORTFOLIO
7.6.3. ELI LILLY & CO. RECENT ACTIVITIES
7.7. EMD SERONO, INC
7.7.1. INTRODUCTION
7.7.2. EMD SERONO, INC PRODUCT PORTFOLIO
7.7.3. EMD SERONO, INC RECENT ACTIVITIES
7.8. ENDO PHARMACEUTICALS INC.
7.8.1. INTRODUCTION
7.8.2. ENDO PHARMACEUTICALS INC. PRODUCT PORTFOLIO
7.8.3. ENDO PHARMACEUTICALS INC. RECENT ACTIVITIES
7.9. FERRING PHARMACEUTICALS
7.9.1. INTRODUCTION
7.9.2. FERRING PHARMACEUTICALS PRODUCT PORTFOLIO
7.9.3. FERRING PHARMACEUTICALS RECENT ACTIVITIES
7.10. GENEA
7.10.1. INTRODUCTION
7.10.2. GENEA PRODUCT PORTFOLIO
7.10.3. GENEA RECENT ACTIVITIES
7.11. GLAXOSMITHKLINE PLC
7.11.1. INTRODUCTION
7.11.2. GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO
7.11.3. GLAXOSMITHKLINE PLC RECENT ACTIVITIES
7.12. HALOTECH DNA
7.12.1. INTRODUCTION
7.12.2. HALOTECH DNA PRODUCT PORTFOLIO
7.12.3. HALOTECH DNA RECENT ACTIVITIES
7.13. IRVINE SCIENTIFIC
7.13.1. INTRODUCTION
7.13.2. IRVINE SCIENTIFIC PRODUCT PORTFOLIO
7.13.3. IRVINE SCIENTIFIC RECENT ACTIVITIES
7.14. JANSSEN PHARMACEUTICAL
7.14.1. INTRODUCTION
7.14.2. JANSSEN PHARMACEUTICAL PRODUCT PORTFOLIO
7.14.3. JANSSEN PHARMACEUTICAL RECENT ACTIVITIES
7.15. MERCK SERONO
7.15.1. INTRODUCTION
7.15.2. MERCK SERONO PRODUCT PORTFOLIO
7.15.3. MERCK SERONO RECENT ACTIVITIES
7.16. NOVARTIS INTERNATIONAL AG
7.16.1. INTRODUCTION
7.16.2. NOVARTIS INTERNATIONAL AG PRODUCT PORTFOLIO
7.16.3. NOVARTIS INTERNATIONAL AG RECENT ACTIVITIES
7.17. ORIGIO
7.17.1. INTRODUCTION
7.17.2. ORIGIO PRODUCT PORTFOLIO
7.17.3. ORIGIO RECENT ACTIVITIES
7.18. OVASCIENCE
7.18.1. INTRODUCTION
7.18.2. OVASCIENCE PRODUCT PORTFOLIO
7.18.3. OVASCIENCE RECENT ACTIVITIES
7.19. PFIZER INC.
7.19.1. INTRODUCTION
7.19.2. PFIZER INC. PRODUCT PORTFOLIO
7.19.3. PFIZER INC. RECENT ACTIVITIES
7.20. PRINCETON BIOMEDITECH CORP.
7.20.1. INTRODUCTION
7.20.2. PRINCETON BIOMEDITECH CORP. PRODUCT PORTFOLIO
7.20.3. PRINCETON BIOMEDITECH CORP. RECENT ACTIVITIES
